Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Israel issues notice that Ben-Gurion Airport flights likely restricted until at least April 16 - 2Explainer-What will change with the US reclassification of marijuana?
- 3Cruising Solo All over the Planet: An Excursion of Self-Disclosure
- 4They died 'doing what they loved': The stories of workers in their 80s who died on the job
- 515 skywatching events you won't want to miss in 2026
- 'Stranger Things' Season 5: When does Volume 2 come out? And Volume 3? Everything to know about the remaining episodes before the finale.
- Moon-bound Artemis II astronauts enjoy a relaxed day in space
- Germany's far-right AfD tops poll ahead of Merz's conservatives
- Woman shocked to welcome baby after experiencing stomach pain on Christmas
- Massachusetts court hears arguments in lawsuit alleging Meta designed apps to be addictive to kids
- 5 Wellbeing Applications Assist You With remaining Fit
- ‘Ukrainian housewives’ and Skyranger delays – German defense poster child Rheinmetall is in hot water
- Step by step instructions to Contrast Lab Precious stones and Normal Jewels
- Blue Origin safely launches wheelchair user to space and back
